blank Quick help
blank Maintenance news

Misleading Register Alert event notification on 15.04.19

Following a clean-up exercise of event information regarding (previously) revoked patents, that were later reinstated, some existing revocation events ("Despatch of communication that patent is revoked") were duplicated on 15.04.2019.

2019.04.15

More...
blank News flashes

Deep link introduced in Malta Register

Click here for more information on the deep linking.

2019.01.28

More...
blank Related links

Extract from the Register of European Patents

Citations: EP2949335

Cited inSearch
Type:Patent literature
Publication No.:US2007161566  [I]
 (PINCHASI IRIT [IL]) [I] 1-15 * paragraphs [0019] , [0021] , [0037]; example 1; claims 1,3 *;
Type:Non-patent literature
Publication information:[A]  - FLECHTER S ET AL, "Comparison of glatiramer acetate (Copaxone(R)) and interferon beta-1b (Betaferon(R)) in multiple sclerosis patients: An open-label 2-year follow-up", JOURNAL OF THE NEUROLOGICAL SCIENCES, (20020515), vol. 197, no. 1-2, ISSN 0022-510X, pages 51 - 55, XP002679780 [A] 1-15 * abstract *
DOI: http://dx.doi.org/10.1016/S0022-510X(02)00047-3
Type:Non-patent literature
Publication information:[A]  - FLECHTER SHLOMO ET AL, "Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration.", CLINICAL NEUROPHARMACOLOGY 2002 JAN-FEB LNKD- PUBMED:11852290, (200201), vol. 25, no. 1, ISSN 0362-5664, pages 11 - 15, XP009161076 [A] 1-15 * abstract * * "Comparison of daily with alternate-day treatment" on page 14 and "Drug Supply" on page 12 *
DOI: http://dx.doi.org/10.1097/00002826-200201000-00002
Type:Non-patent literature
Publication information:[A]  - KHAN O ET AL, "Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every - other - day injections in relapsing -remitting multiple", MULT.SCLER. (14, SUPPL. 1, S296, 2008) 0 REF. ISSN: 1352-4585 AV - WAYNE STATE UNIV, SCH MED, DETROIT, MI, USA., (2008), XP009161078 [A] 1-15 * abstract *
Type:Non-patent literature
Publication information:[A]  - CAON CHRISTINA ET AL, "Randomized, Prospective, Rater-Blinded, Four Year Pilot Study To Compare the Effect of Daily Versus Every Other Day Glatiramer Acetate 20 mg Subcutaneous Injections in RRMS", NEUROLOGY, & 61ST ANNUAL MEETING OF AMERICAN-ACADEMY-OF-NEUROLOGY; SEATTLE, WA, USA; APRIL 28 -29, 2009, (200903), vol. 72, no. 11, Suppl. 3, ISSN 0028-3878, page A317, XP009161100 [A] 1-15 * abstract *
Type:Non-patent literature
Publication information:[I]  - COHEN J A ET AL, "Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.", NEUROLOGY 20 MAR 2007 LNKD- PUBMED:17372130, (20070320), vol. 68, no. 12, ISSN 1526-632X, pages 939 - 944, XP002679784 [I] 1-15 * abstract *
DOI: http://dx.doi.org/10.1212/01.wnl.0000257109.61671.06
Type:Non-patent literature
Publication information:[A]  - SIMPSON DENE ET AL, "Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis.", CNS DRUGS, (2002), vol. 16, no. 12, ISSN 1172-7047, pages 825 - 850, XP009161077 [A] 1-15 * "Therapeutic efficacy" on page 835 and "Dosage and Administration" on page 844 * * table II *
DOI: http://dx.doi.org/10.2165/00023210-200216120-00004
Type:Non-patent literature
Publication information:[I]  - Anonymous, "Teva Provides Update on FORTE Trial", (20080707), Internet, URL: http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1554743, (20150831), XP002743817 [I] 1-15 * abstract *
Type:Non-patent literature
Publication information:[I]  - YONG WEE V ET AL, "Immunological Responses to Different Doses of Glatiramer Acetate in MS: Analyses from the FORTE Trial", NEUROLOGY, & 61ST ANNUAL MEETING OF AMERICAN-ACADEMY-OF-NEUROLOGY; SEATTLE, WA, USA; APRIL 28 -29, 2009, (200903), vol. 72, no. 11, Suppl. 3, ISSN 0028-3878, page A39, XP002743818 [I] 1-15 * abstract *
Cited inOpposition
Type:Patent literature
Publication No.:WO2007081975  
Type:Patent literature
Publication No.:WO2011022063  
Type:Patent literature
Publication No.:WO2011022063  
 * (the parent application as filed); *
Type:Patent literature
Publication No.:US2007161566  
Type:Patent literature
Publication No.:EP2949335  
 * ; * * ; *
Type:Patent literature
Publication No.:WO0020010  
Type:Non-patent literature
Publication information:   - "View of NCT01067521", ClinicalTrials.gov archive, (20100210), XP055508500
Type:Non-patent literature
Publication information:   - "FDA label Rebif PI", www.accessdata.fda.gov, (20020308), URL: https://www.accessdata.fda.gov/drugsatfda_docs/)abe)/2002/ifnbs er030702LB.pdf, XP055508530
Type:Non-patent literature
Publication information:   - J.J Jessop, "Review and Evaluation of Pharmacology Toxicology Data", Original NDA Review, NDA 20-622, Copolymer-1 for treatment of relaps- ing-remitting multiple sclerosis, (19960000), XP055508552
Type:Non-patent literature
Publication information:   - Grennero Alfonso, Remington's Pharmaceutical Sciences, Easton, Pennsylvania, Mack Publishing Company, (19900000), pages 1813 - 1827, XP055508569
Type:Non-patent literature
Publication information:   - KHAN O. et al., "Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every-other-day glatiramer acetate 20 mg subcutaneous injections in relapsing- remitting multiple sclerosis", Multiple Sclerosis, (20080900), vol. 14, page S296, XP009161078
Type:Non-patent literature
Publication information:   - GAGNON L., "Every-Other-Day Dosing of Glatiramer Acetate Reduces Adverse Reactions with Comparable Efficacy to Daily Dosing", WCTRMS, (20080921), XP055508581
DOI: http://dx.doi.org/http://www.peervoice.com/every-other-day-dosing-glatiramer-acetate-reduces-adverse-reactions-comparable-efficacy-daily-dosing-presented-wctrms#
Type:Non-patent literature
Publication information:   - BEJAOUI K. et al., "There is no rebound worsening of multiple sclero- sis after stopping disease-modifying therapies", Multiple Sclerosis, (20080000), vol. 14, pages S31 - S32, XP055508582
Type:Non-patent literature
Publication information:   - FLECHTER et al., "Comparison of glatiramer acetate (Copaxone(R)) and interferon beta-1b (Betaferon(R)) in multiple sclerosis patients: An open-label 2-year follow-up", J Neurol Sci, (20020515), vol. 197, no. 1-2, pages 51 - 55, XP002679780
DOI: http://dx.doi.org/10.1016/S0022-510X(02)00047-3
Type:Non-patent literature
Publication information:   - FLECHTER et al., "Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: Open multicenter study of alternate-day administration", Clin Neuropharm, (20020000), vol. 25, no. 1, pages 11 - 15, XP009161076
DOI: http://dx.doi.org/10.1097/00002826-200201000-00002
Type:Non-patent literature
Publication information:   - KHAN et al., "P902 Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every - other - day glatiramer acetate 20 mg subcutaneous injections in relapsing -remitting multiple sclerosis", Multiple Sclerosis, (20080000), vol. 14, page S296, XP009161078
Type:Non-patent literature
Publication information:   - CAON et al., "P06.141 Randomized, Prospective, Rater-Blinded, Four Year Pilot Study To Compare the Effect of Daily Versus Every Other Day Glatiramer Acetate 20 mg Subcutaneous Injections in RRMS", Neurology, (20090317), vol. 72, no. 11, page 3, XP009161100
Type:Non-patent literature
Publication information:   - COHEN et al., "Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS", Neurology, (20070000), vol. 68, no. 12, pages 939 - 944, XP002679784
DOI: http://dx.doi.org/10.1212/01.wnl.0000257109.61671.06
Type:Non-patent literature
Publication information:   - SIMPSON et al., "Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis", CNS D, (20020000), pages 825 - 850, XP009161077
DOI: http://dx.doi.org/10.2165/00023210-200216120-00004
Type:Non-patent literature
Publication information:   - "Teva to Present Positive Data for Glatiramer Acetate 40 mg/1 ml Given Three Times Weekly for Relapsing-Remitting MS", Teva press release, (20121010), URL: http://www.tevapharm.com/Media/News/Pages/2012/1743500.aspx?year=2012&page..., XP055607303
Type:Non-patent literature
Publication information:   - KHAN et al., "A phase 3 trial to assess the efficacy and safety of glatiramer acetate injections 40mg administered 3 times a week compared to placebo", Abstract presented at 28th Congress of the European Committee for treatment and research in multiple sclerosis, (20121010), XP055607318
Type:Non-patent literature
Publication information:   - "Copaxone 20mg/ml, Solution For Injection, Pre-Filled Syringe", Copaxone UK product label ;, (20090417), pages 1 - 7, XP055579983
Type:Non-patent literature
Publication information:   - "(P01.124) Immunological Responses to Different Doses of Glatiramer Acetate in MS: Analyses from the FORTE Trial", NEUROLOGY; 61st Annual Meeting of American-Academy-of-Neurology; Seattle, WA, USA, April 28 - 29, 2009,, (20090428), vol. 72, XP002743818
Type:Non-patent literature
Publication information:   - "Results from a phase III, one-year randomized, double-blind, parallel-group, dose-comparison study with glatiramer acetate in relapsing-re", World Congress on Treatment and Research in Multiple Sclerosis, (20080000), XP055607341
Type:Non-patent literature
Publication information:   - "Teva initiates phase III study to confirm increased efficacy of higher dose of Glatiramer Acetate for the treatment of relapsing-remitting Multiple Sclerosis", Teva press releases, (20060000), XP055581348 * (D13) and 2007 (D14); *
Type:Non-patent literature
Publication information:   - "Data Published in Neurology showed that higher dosie of Copaxone(R) increased efficacy in relapsing remitting Mutiple Sclerosis (Rrms)", (20070417), URL: http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1554611, XP055581344
Type:Non-patent literature
Publication information:   - "Doubling the Dose of Glatiramer Acetate Does Not Increase Efficacy", MedScape, (20080922), XP055579985
Type:Non-patent literature
Publication information:   - Shi et al., "mpact of dose frequency on compliance and health outcomes: a literature review (1966-2006)", Expert Rev. Pharmacoeconomics Outcomes Res., (20070000), vol. 7, no. 2, pages 187 - 202, XP055579988
DOI: http://dx.doi.org/10.1586/14737167.7.2.187
Type:Non-patent literature
Publication information:   - Costello et al., "Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term", Medscape J Med., (20080930), vol. 10, no. 9, page 225, XP055579991
Type:Non-patent literature
Publication information:   - "Product Life-Cycle Management for Injectable Drugs: A Good Outlook for Proactive Market players", (20061202), Pharmtech, URL: http://www.pharmtech.com/product-life-cycle-management-injectable-drugs-good-outlook- proactive-market-players, XP055579996
Type:Non-patent literature
Publication information:   - M. ROVARIS et al., "Results of a randomised, double-blind, parallel-group study assessing safety and efficacy of 40 mg vs. 20 mg of glatiramer acetate on MRI-measured disease activity in relapsing-remitting multiple sclerosis", Multiple Sclerosis, (20060531), vol. 12, no. Suppl. 1, page 585, XP009157336
Type:Non-patent literature
Publication information:   - DEVONSHIRE et al., "P316 The Global Adherence Project - A multicentre observational study on adherence to disease-modifying therapies in patients suffering from relapsing-remitting multiple sclerosis", Mult. Scler., (20060000), vol. 12, no. S1, page S82, XP055579999
Type:Non-patent literature
Publication information:   - "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers", Journal of Parenteral Science and Technology, (19880000), vol. 42, no. 2S, pages S1 - S26, XP055253757
Type:Non-patent literature
Publication information:   - National litigation referred to in section 1.2(c) above, German nullity claim
Type:Non-patent literature
Publication information:   - Multiple Sclerosis, (20090000), vol. 15, pages S249 - S250
Type:Non-patent literature
Publication information:   - FLECHTER et al., "Comparison of glatiramer acetate (Copaxone(R)) and interferon beta-1b (Betaferon(R)) in multiple sclerosis patients: An open-label 2-year follow-up", J Neurol Sci, (20020515), vol. 197, pages 51 - 55, XP002679780
DOI: http://dx.doi.org/10.1016/S0022-510X(02)00047-3
Type:Non-patent literature
Publication information:   - FLECHTER et al., "Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration", Clin Neuropharm, (20020000), vol. 25, no. 1, pages 11 - 15, XP009161076
DOI: http://dx.doi.org/10.1097/00002826-200201000-00002
Type:Non-patent literature
Publication information:   - KHAN et al., "P902 Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every - other - day glatiramer acetate 20 mg subcutaneous injections in relapsing -remitting multiple sclerosis", Multiple Sclerosis, (20080000), vol. 14, page S296
Type:Non-patent literature
Publication information:   - CAON et al., "P06.141 Randomized, Prospective, Rater-Blinded, Four Year Pilot Study To Compare the Effect of Daily Versus Every Other Day Glatiramer Acetate 20 mg Subcutaneous Injections in RRMS", Neurology, (20090317), vol. 72, no. 11, page A317, XP009161100 * ) Suppl 3; *
Type:Non-patent literature
Publication information:   - SIMPSON et al., "Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis", CNS Drugs, (20020000), pages 925 - 850, XP009161077
DOI: http://dx.doi.org/10.2165/00023210-200216120-00004
Type:Non-patent literature
Publication information:   - "Teva to Present Positive Data for Glatiramer Acetate 40 mg/1 ml Given Three Times Weekly for Relapsing-Remitting MS", (20121010), Teva, URL: http://www.tevapharm.com/Media/News/Pages/2012/1743500.aspx?year=2012&page..., XP055607303
Type:Non-patent literature
Publication information:   - KHAN et al., "A phase 3 trial to assess the efficacy and safety of glatiramer acetate injections 40mg administered 3 times a week compared to placebo", 28th Congress of the European Committee for treatment and research in multiple sclerosis, (20121010), XP055607318
Type:Non-patent literature
Publication information:   - "Copaxone 20mg/ml, Solution For Injection, Pre-Filled Syringe", pages 1 - 7, Teva Pharmaceuticals, URL: www.medicines.org.uk/EMC/printfriendlydocument.aspx?documentid=17516, XP055579983
Type:Non-patent literature
Publication information:   - "(P01.124) Immunological Responses to Different Doses of Glatiramer Acetate in MS: Analyses from the FORTE Trial", 61st Annual Meeting of American-Academy-of-Neurology; Seattle, WA, USA, April 28 - 29, 2009, vol. 11, no. 3, suppl, (20090428), NEUROLOGY, URL: NEUROLOGY; 61st Annual Meeting of American-Academy-of-Neurology; Seattle, WA, USA, April 28 - 29, 2009, XP002743818
Type:Non-patent literature
Publication information:   - Giancarlo Comi, "Results from a phase III, one-year randomized, double-blind, parallel-group, dose-comparison study with glatiramer acetate in relapsing-remitting multiple sclerosis", (20080000), World Congress on Treatment and Research in Multiple Sclerosis, URL: http://www.multiwebcast.com/wctrims/2008/msmontreal/2448/chair.giancarlo.com.r..., XP055607341
Type:Non-patent literature
Publication information:   - "Teva initiates phase III study to confirm increased efficacy of higher dose of Glatiramer Acetate for the treatment of relapsing-remitting Multiple Sclerosi", Teva press releases, (20060000), URL: http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1557343, XP055581348 * ); *
Type:Non-patent literature
Publication information:   - "Data Publised In Neurology Showed That Higher Dose Of Copaxone(R) increased Efficacy in Relapsing-Remitting Multiple Sclerosis (Rrms)", Teva News Release, URL: http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1554611, XP055607348
Type:Non-patent literature
Publication information:   - Alison Palkhivala, "Doubling the Dose of Glatiramer Acetate Does Not Increase Efficacy", MedScape, (20080922), URL: https://www.medscape.com/viewarticle/580865, XP055579985
Type:Non-patent literature
Publication information:   - "Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006)", Expert Rev. Pharmacoeconomics Outcomes Res., (20070000), vol. 7, no. 2, pages 187 - 202, XP055579988
DOI: http://dx.doi.org/10.1586/14737167.7.2.187
Type:Non-patent literature
Publication information:   - Costello et al., "Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term", Medscape J Med., vol. 10, no. 9, (20080930), URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2580090/?report=printable, XP055579991
Type:Non-patent literature
Publication information:   - "Product Life-Cycle Management for Injectable Drugs: A Good Outlook for Proactive", (20061202), Pharmteceutical Technology, URL: http://www.pharmtech.com/product-life-cycle-management-injectable-drugs-good-outlook- proa ctive-ma rket-pl avers, (20160115), XP055579996
Type:Non-patent literature
Publication information:   - M. ROVARIS et al., "Results of a randomised, double-blind, parallel-group study assessing safety and efficacy of 40 mg vs. 20 mg of glatiramer acetate on MRI-measured disease activity in relapsing-remitting multiple sclerosis", Multiple Sclerosis, (20060531), vol. 12, no. 1, page 585, XP009157336 * , et al; *
Type:Non-patent literature
Publication information:   - DEVONSHIRE et al., "P316 The Global Adherence Project - A multicentre observational study on adherence to disease-modifying therapies in patients suffering from relapsing- remitting multiple sclerosis", Mult. Scler., (20061200), vol. SI, XP055579999 * et al; *
Cited inby applicant
Type:Patent literature
Publication No.:US2002055466  
Type:Patent literature
Publication No.:US2005014694  
Type:Patent literature
Publication No.:US2002077278  
Type:Patent literature
Publication No.:US2003004099  
Type:Patent literature
Publication No.:US2002037848  
Type:Patent literature
Publication No.:US6514938  
Type:Patent literature
Publication No.:WO0160392  
Type:Patent literature
Publication No.:WO0027417  
Type:Patent literature
Publication No.:WO0197846  
Type:Patent literature
Publication No.:US2008013146  
Type:Patent literature
Publication No.:WO2009070298  
Type:Patent literature
Publication No.:US2009149541  
Type:Non-patent literature
Publication information:   - G. COMI ET AL., "European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetere on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients with Relapsing Multiple Sclerosis", ANN. NEUROL., (2001), vol. 49, doi:doi:10.1002/ana.64, pages 290 - 297, XP009042363
DOI: http://dx.doi.org/10.1002/ana.64
Type:Non-patent literature
Publication information:   - POSER ET AL., NEUROLOGY, (198303), vol. 13, no. 3, pages 227 - 230
Type:Non-patent literature
Publication information:   - ANN NEUROL, (2005), vol. 58, pages 840 - 846
Type:Non-patent literature
Publication information:   - KANSARA V; MITRA A; WU Y, "Subcutaneous Delivery", DRUG DELIV TECHNOL, (200906), vol. 9, no. 6, pages 38 - 42
Type:Non-patent literature
Publication information:   - LUCA DURELLI, J NEUROL, (2003), no. 4, page 250
Cited inother
Type:Patent literature
Publication No.:US8969302  
Type:Patent literature
Publication No.:US8399413  
Type:Patent literature
Publication No.:EP2405749  
Type:Non-patent literature
Publication information:   - Y.-C. J. WANG, "PARENTERAL FORMULATIONS OF PROTEINS AND PEPTIDES: STABILITY AND STABILIZERS", J. Parent. Sci. Techn., (19880000), vol. 42, no. 2S, pages S4 - S26, XP000984636